SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion centers on Trumps Iran policy and its perceived effects on fuel prices, inflation, and the economy, alongside speculation about political backlash in the midterms. Many traders are bearish on DJT and criticize its weak share performance, though some post short-term bullish or swing-trading views.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is drawing attention amid a persistent selloff and repeated 52-week lows, with traders focused on its earnings-related guidance cut, weaker business trends, and doubts about managements execution. Some see the valuation as attractive and point to a possible turnaround or asset sales, while others expect further weakness; takeover and short-seller manipulation claims remain speculation.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

QNTs sharp rally and repeated attempts to break resistance are driving attention, with bullish traders linking the move to Quants banking and interoperability narrative and anticipated updates around SIBOS and the Clearing House initiative. Others point to failed breakouts, profit-taking, and the tokens sharp swings as reasons for caution.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

WLDs rally and breakout are drawing attention, with traders citing Grayscales proposed ETF filing, Eightcos large token holdings and the proof-of-humanity use case amid growing AI-agent activity. Sentiment is broadly bullish but volatile, with some traders accusing Arthur Hayes of promoting tokens before selling and warning that the move may be speculative.

GLOBALFOUNDRIES, Inc. provides foundry services and manufactures semiconductors. It offers global shuttle, mask, post-fab and turnkey services. The company was founded on October 7, 2008 and is headquartered in Malta, NY.

GlobalFoundries Inc

GlobalFoundries expanded multi-year SiGe capacity deal with Marvell for AI data-center optical connectivity is a prominent catalyst, reinforcing traders interest in its photonics and foundry exposure. Many see the shares as undervalued, while others question the stocks weak or uneven performance despite the positive AI-related story.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

Reports that the federal government is preparing a multibillion-dollar loan for Vistra nuclear plant upgrades are driving attention, with traders viewing the financing as support for expanding power supply amid AI and data-center demand. The news has drawn bullish buying interest, though some question the benefit of a loan and point to the stocks volatile price action and debt concerns.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is drawing attention after Kodiaks positive Zenkuda trial results intensified competition in wet AMD and coincided with a sharp selloff in OCUL. Traders disagree on whether the readout undermines AXPAXLIs prospects: bears see a higher competitive bar, while bulls argue the trial results are not directly comparable and point to AXPAXLIs potential durability and pending NDA path.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddits sharp, choppy pullback and repeated struggle to reclaim $150 dominate discussion, with traders pointing to Metas forum-app launch and uncertainty around AI data licensing as possible headwinds. Bulls argue Reddits data and growth remain valuable, while bears focus on weak price action and executive share sales.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

A sharp pullback on thin trading has traders debating whether technical selling and short pressurenot a clear new company catalystare driving weakness. Bulls are accumulating ahead of the next earnings report and CEO strategy update, with Disney/Hulu integration as a longer-term thesis, while bears expect further declines.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Attention centers on upcoming DM1 and FSHD clinical data, alongside Elevidys safety and regulatory updates, as traders look for evidence that could rebuild confidence in Sareptas pipeline and Duchenne franchise. Novartis failed DM1 trial has fueled concern that RNA knockdown may not translate into functional benefit, though others argue Sareptas different delivery approach makes its results distinct; buyout and short-squeeze talk remains speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen Platform Update on October 5, 2026

Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen Platform Update on October 5, 2026 Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen Platform Update on October 5, 2026PR NewswireHOLON, Israel, Sept. 22, 2026 HOLON, Israel, Sept. 22, 2026 /PRNewswire...

Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference PR Newswire HOLON, Israel, Sept. 8, 2026 HOLON, Israel, Sept. 8, 2026 /PRNewswire...

All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Are Medical Stocks Lagging  Compugen (CGEN) This Year?

Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.

Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates

Compugen (CGEN) delivered earnings and revenue surprises of 0.00% and -3.63%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Compugen Reports Second Quarter 2026 Results

Compugen Reports Second Quarter 2026 Results Compugen Reports Second Quarter 2026 Results PR Newswire HOLON, Israel, Aug. 3, 2026 COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the interim analysis expected by Q1 2027Trial-in-progress poster on...

Compugen to Participate in BTIG Biotechnology Conference 2026

Compugen to Participate in BTIG Biotechnology Conference 2026 Compugen to Participate in BTIG Biotechnology Conference 2026 PR Newswire HOLON, Israel, July 21, 2026 HOLON, Israel, July 21, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company...

Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026

Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026 Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026 PR Newswire HOLON, Israel, July 20, 2026 HOLON, Israel, July 20, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage...

Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress

Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress PR Newswire HOLON, Israel, June 18, 2026...

Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026

Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 PR Newswire HOLON, Israel, June 11, 2026 HOLON, Israel, June 11, 2026...

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Compugen Ltd

Neutral Sentiment

Up more than 5%

Flat to up 5%

Flat to down 5%

Down more than 5%

What&#39;s your expected total return for the S&amp;P 500 ($SPY) in Q4? 

Drop your reasoning in the comments.

Stocktwits

What's your expected total return for the S&P 500 (

) in Q4? 

Drop your reasoning in the comments.

CGEN Compugen Ltd